Real-World Outcomes of Rituximab in Pemphigus: An Australian Tertiary Cohort.

Authors

Pokphazz Christjaroon, Ali Abid, Orli Wargon, Paul Weller, Artiene Tatian

Published in

The Australasian journal of dermatology. Oct 17, 2026. Epub Oct 17, 2026.

Abstract

Rituximab is endorsed internationally as first-line therapy for moderate-to-severe pemphigus, but Australian guidelines position it as a rescue agent and local outcome data are limited. In this single-centre retrospective cohort, 24 adults with pemphigus vulgaris (n = 16) or pemphigus foliaceus (n = 8) received rituximab as part of routine care; median follow-up from first infusion was 24.9 months. Disease control was documented in all patients and complete remission in 20 (83%), of whom half subsequently relapsed despite most receiving more than one cycle. Adverse events occurred in eight patients (33%), predominantly mild infusion-related reactions, with one fatal pneumonia. These real-world data support planned maintenance after remission rather than single-course rescue use, and prospective multicentre study with standardised severity scoring.

PMID:
42888936
Bibliographic data and abstract were imported from PubMed on 17 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.